Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06824168 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
A Phase 2 study of Acute Myeloid Leukemia and Leukemia, sponsored by Daiichi Sankyo.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
- 20
- Study locations
NCT06824168 is a Phase 2 study of Acute Myeloid Leukemia and Leukemia that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 130 participants, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (13% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT06824168, a Phase 2 study of Acute Myeloid Leukemia and Leukemia, is actively recruiting participants, sponsored by Daiichi Sankyo.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical two-arm trial is designed to evaluate two doses of quizartinib as maintenance therapy after induction/consolidation in participants with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) (+) acute myeloid leukemia (AML) in first complete remission (CR) who have not received allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Conditions Studied
Interventions
- DRUG Quizartinib High Dose
- DRUG Quizartinib Low Dose
Study Locations (20)
Other
- Royal Adelaide Hospital - Adelaide
- Austin Health - Australia
- St. Vincent's Hospital Melbourne - Darlinghurst
- The Alfred Hospital - Melbourne
- Royal Perth Hospital - Perth
- Gold Coast University Hospital - Southport
- Westmead Hospital - Sydney
- Hospital Erasto Gaertner - Liga Paranaense de Combate ao Cancer - Curitiba
- Cetus Hospital Dia Oncologia - Minas Gerai
- Hospital de Clínicas de Porto Alegre - Porto Alegre
- Irmandade da Santa Casa de Misericórdia de Porto Alegre Centro Multidisciplinar de Pesquisa - Porto Alegre
New York
- Roswell Park Cancer Institute - Buffalo
- Weill Cornell - New York
- Westchester Medical College - Valhalla
- Clinical Research Allicance - Westbury
Texas
- The Methodist Hospital Research Institute - Houston
- The University of Texas MD Anderson Cancer Center - Houston
Maryland
- John Hopkins School of Medicine - Baltimore
Massachusetts
- Umass Memorial Health Care Systems - Worcester
Pennsylvania
- Spoknwrd Clinical Trials Inc. - Easton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2025-07-18 |
| Est. Completion | 2032-07-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06824168
The ClinicalTrials.gov registry entry for NCT06824168 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (13% higher). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Quizartinib High Dose is the first listed.
NCT06824168 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT06824168 about?
NCT06824168 is a clinical study titled "Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission". This clinical two-arm trial is designed to evaluate two doses of quizartinib as maintenance therapy after induction/consolidation in participants with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) (+) acute myeloid leukemia (AML) in first complete remission (CR) who have not re...
What is the current status of trial NCT06824168?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2025-07-18. Estimated completion is 2032-07-14.
What conditions does trial NCT06824168 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Leukemia.
What interventions are being tested in trial NCT06824168?
The interventions under investigation include: Quizartinib High Dose (DRUG), Quizartinib Low Dose (DRUG).
Who is sponsoring clinical trial NCT06824168?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06824168 being conducted?
This trial has 20 study locations across Maryland, Massachusetts, New York, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
RECRUITING · Phase 2
-
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
RECRUITING · Phase 2
-
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
RECRUITING · Phase 2
-
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.